Oncological safety and functional outcomes of testosterone replacement therapy in symptomatic adult-onset hypogonadal prostate cancer patients following robot-assisted radical prostatectomy.

导出 LinkOut

翻译打印收藏纠错

作者： Hanna,Shahine ^[1] ; Marc,Zanaty ^[2] ; Ahmed S,Zakaria ^[1] ; David-Dan,Nguyen ^[3] ; Felix,Couture ^[4] ; Iman,Sadri ^[5] ; Russel,Schwartz ^[1] ; Adel,Arezki ^[5] ; Dean,Elterman ^[6] ; Assaad,El-Hakim ^[7] ; Kevin C,Zorn ^[8]

作者单位： Département d'Urologie, Robotic Surgery, Centre Hospitalier de l'Université de Montréal, Montreal, Canada. ^[1] Department of Urology, Hopital Rouyn-Noranda, Quebec, Canada. ^[2] Faculty of Medicine, McGill University, Montreal, Canada. ^[3] Département d'Urologie, Centre Hospitalier de l'Université de Sherbrooke, Montreal, Canada. ^[4] School of Medicine, McGill University, Montreal, Canada. ^[5] Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. ^[6] Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada. ^[7] Département d'Urologie, Robotic Surgery, Centre Hospitalier de l'Université de Montréal, Montreal, Canada. zorn.chumurology@gmail.com. ^[8] Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada. zorn.chumurology@gmail.com. ^[9]

关键词 Oncological outcomes Prostate cancer Robotic-assisted radical prostatectomy Testosterone replacement therapy